Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC

NCT06863506 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

78

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Non-small Cell Lung Cancer)

Interventions

DRUG: befotertinib

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]